Sirpa Leppä

11.9k total citations
177 papers, 4.7k citations indexed

About

Sirpa Leppä is a scholar working on Pathology and Forensic Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Sirpa Leppä has authored 177 papers receiving a total of 4.7k indexed citations (citations by other indexed papers that have themselves been cited), including 124 papers in Pathology and Forensic Medicine, 88 papers in Oncology and 43 papers in Molecular Biology. Recurrent topics in Sirpa Leppä's work include Lymphoma Diagnosis and Treatment (124 papers), CAR-T cell therapy research (36 papers) and Chronic Lymphocytic Leukemia Research (33 papers). Sirpa Leppä is often cited by papers focused on Lymphoma Diagnosis and Treatment (124 papers), CAR-T cell therapy research (36 papers) and Chronic Lymphocytic Leukemia Research (33 papers). Sirpa Leppä collaborates with scholars based in Finland, Denmark and Norway. Sirpa Leppä's co-authors include Dirk Bohmann, Marja‐Liisa Karjalainen‐Lindsberg, Minna Taskinen, Minna Eriksson, Lea Sistonen, Heidi Nyman, Markku Jalkanen, Suvi‐Katri Leivonen, Mats Jerkeman and Harald Holte and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Sirpa Leppä

165 papers receiving 4.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sirpa Leppä Finland 36 1.9k 1.9k 1.8k 879 695 177 4.7k
Tarik Möröy Germany 54 1.2k 0.6× 4.6k 2.5× 2.2k 1.2× 2.5k 2.9× 552 0.8× 166 8.7k
Vundavalli V. Murty United States 40 1.2k 0.6× 4.4k 2.4× 1.9k 1.1× 939 1.1× 632 0.9× 109 7.2k
Elizabeth W. Newcomb United States 43 947 0.5× 3.4k 1.8× 2.6k 1.4× 1000 1.1× 1.9k 2.8× 81 6.5k
Finbarr E. Cotter United Kingdom 38 1.2k 0.6× 2.6k 1.4× 1.3k 0.7× 792 0.9× 872 1.3× 111 5.0k
Michael A. Rieger Germany 37 525 0.3× 2.4k 1.3× 835 0.5× 976 1.1× 793 1.1× 145 4.9k
Jan Köster Netherlands 46 666 0.3× 5.6k 3.0× 2.2k 1.2× 687 0.8× 731 1.1× 190 8.5k
Svetlana Pack United States 47 690 0.4× 3.1k 1.7× 1.5k 0.9× 388 0.4× 467 0.7× 130 6.5k
Pierre Dubus France 42 1.1k 0.6× 5.3k 2.8× 4.0k 2.3× 1.1k 1.2× 642 0.9× 163 9.7k
Hua Han China 47 517 0.3× 5.0k 2.7× 1.1k 0.6× 2.0k 2.3× 408 0.6× 185 7.9k
Minhong Yan United States 33 464 0.2× 3.9k 2.1× 1.4k 0.8× 3.0k 3.4× 523 0.8× 51 7.6k

Countries citing papers authored by Sirpa Leppä

Since Specialization
Citations

This map shows the geographic impact of Sirpa Leppä's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sirpa Leppä with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sirpa Leppä more than expected).

Fields of papers citing papers by Sirpa Leppä

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sirpa Leppä. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sirpa Leppä. The network helps show where Sirpa Leppä may publish in the future.

Co-authorship network of co-authors of Sirpa Leppä

This figure shows the co-authorship network connecting the top 25 collaborators of Sirpa Leppä. A scholar is included among the top collaborators of Sirpa Leppä based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sirpa Leppä. Sirpa Leppä is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Meriranta, Leo, Arne Kolstad, Martin Hutchings, et al.. (2025). Circulating tumor DNA determinants of response and outcome in relapsed/refractory mantle cell lymphoma. Blood Advances. 9(17). 4528–4541. 1 indexed citations
3.
4.
5.
Monzó, Héctor J., Marko Hyytiäinen, Lidia Moyano‐Galceran, et al.. (2023). Efficacy and Safety of Glycosphingolipid SSEA-4 Targeting CAR-T Cells in an Ovarian Carcinoma Model. Molecular Cancer Therapeutics. 22(11). 1319–1331. 14 indexed citations
6.
Leivonen, Suvi‐Katri, et al.. (2023). Intra-patient evolution of tumor microenvironment in the pathogenesis of treatment-naïve metastatic melanoma patients. Acta Oncologica. 62(9). 1008–1013. 1 indexed citations
7.
Dickinson, Michael, Carmelo Carlo‐Stella, Franck Morschhauser, et al.. (2021). Glofitamab Monotherapy Provides Durable Responses after Fixed-Length Dosing in Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) Patients (pts). Blood. 138(Supplement 1). 2478–2478. 9 indexed citations
8.
Leivonen, Suvi‐Katri, Maja Ludvigsen, Harald Holte, et al.. (2021). Soluble PD-1 but Not PD-L1 Levels Predict Poor Outcome in Patients with High-Risk Diffuse Large B-Cell Lymphoma. Cancers. 13(3). 398–398. 18 indexed citations
9.
Meriranta, Leo, Amjad Alkodsi, Annika Pasanen, et al.. (2021). Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma. Blood. 139(12). 1863–1877. 71 indexed citations
10.
Tanskanen, Tomas, et al.. (2021). Transformation and outcome of nodular lymphocyte predominant Hodgkin lymphoma: a Finnish Nationwide population-based study. Blood Cancer Journal. 11(12). 203–203. 6 indexed citations
11.
Autio, Matias, Suvi‐Katri Leivonen, Oscar Brück, et al.. (2021). Clinical Impact of Immune Cells and Their Spatial Interactions in Diffuse Large B-Cell Lymphoma Microenvironment. Clinical Cancer Research. 28(4). 781–792. 35 indexed citations
12.
Leivonen, Suvi‐Katri, Oscar Brück, Marja‐Liisa Karjalainen‐Lindsberg, et al.. (2020). Prognostic Impact of Tumor-Associated Macrophages on Survival Is Checkpoint Dependent in Classical Hodgkin Lymphoma. Cancers. 12(4). 877–877. 35 indexed citations
13.
14.
Meriranta, Leo, Annika Pasanen, Amjad Alkodsi, et al.. (2020). Molecular background delineates outcome of double protein expressor diffuse large B-cell lymphoma. Blood Advances. 4(15). 3742–3753. 19 indexed citations
15.
Pellinen, Teijo, et al.. (2020). Adverse prognostic impact of regulatory T‐cells in testicular diffuse large B‐cell lymphoma. European Journal Of Haematology. 105(6). 712–721. 10 indexed citations
16.
Alkodsi, Amjad, Alejandra Cervera, Kaiyang Zhang, et al.. (2019). Distinct subtypes of diffuse large B-cell lymphoma defined by hypermutated genes. Leukemia. 33(11). 2662–2672. 22 indexed citations
17.
Häkkinen, Antti, Amjad Alkodsi, Kaiyang Zhang, et al.. (2018). Identifying differentially methylated sites in samples with varying tumor purity. Bioinformatics. 34(18). 3078–3085. 3 indexed citations
18.
Fosså, Alexander, Helen Goergen, Peter Kamper, et al.. (2018). B-CAP (brentuximab vedotin, cyclophosphamide, doxorubicin and predniso(lo)Ne) in Older Patients with Advanced-Stage Hodgkin Lymphoma: Results of a Phase II Intergroup Trial By the German Hodgkin Study Group (GHSG) and the Nordic Lymphoma Group (NLG). Kölner Universitäts PublikationsServer (Universität zu Köln).
19.
Leivonen, Suvi‐Katri, Amjad Alkodsi, Alejandra Cervera, et al.. (2017). MicroRNAs regulate key cell survival pathways and mediate chemosensitivity during progression of diffuse large B-cell lymphoma. Blood Cancer Journal. 7(12). 654–654. 28 indexed citations
20.
Taskinen, Minna, Erkka Valo, Marja‐Liisa Karjalainen‐Lindsberg, et al.. (2010). Signal Transducers and Activators of Transcription 5a–Dependent Cross-talk between Follicular Lymphoma Cells and Tumor Microenvironment Characterizes a Group of Patients with Improved Outcome after R-CHOP. Clinical Cancer Research. 16(9). 2615–2623. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tarik Möröy Breakdown of academic impact, for papers by Vundavalli V. Murty Breakdown of academic impact, for papers by Elizabeth W. Newcomb Breakdown of academic impact, for papers by Finbarr E. Cotter Breakdown of academic impact, for papers by Michael A. Rieger Breakdown of academic impact, for papers by Jan Köster Breakdown of academic impact, for papers by Svetlana Pack Breakdown of academic impact, for papers by Pierre Dubus Breakdown of academic impact, for papers by Hua Han Breakdown of academic impact, for papers by Minhong Yan
Rankless by CCL
2026